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Cardiospheres (CSs) are self-assembling multicellular clusters from the cellular outgrowth from cardiac explants cultured in
nonadhesive substrates. They contain a core of primitive, proliferating cells, and an outer layer of mesenchymal/stromal cells and
differentiating cells that express cardiomyocyte proteins and connexin 43. Because CSs contain both primitive cells and committed
progenitors for the three major cell types present in the heart, that is, cardiomyocytes, endothelial cells, and smooth muscle cells,
and because they are derived from percutaneous endomyocardial biopsies, they represent an attractive cell source for cardiac
regeneration. In preclinical studies, CS-derived cells (CDCs) delivered to infarcted hearts resulted in improved cardiac function.
CDCs have been tested safely in an initial phase-1 clinical trial in patients after myocardial infarction. Whether or not CDCs are
superior to purified populations, for example, c-kit+ cardiac stem cells, or to gene therapy approaches for cardiac regeneration
remains to be evaluated.
1. Introduction
Myocardial infarction (MI) and the subsequent development
of congestive heart failure are the leading cause of mortality
in industrialized countries. MI causes a sudden and dramatic
loss of contractile heart muscle cells, or cardiomyocytes,
healingwith scarring.The surviving cardiomyocytes undergo
hypertrophy and the heart remodels. These adaptive mech-
anisms are detrimental in the long run, eventually leading
to pump failure. Hence, there is a pressing need for recon-
stituting contractile cardiac tissue after acute MI as well as in
chronic heart failure, for example, in dilated cardiomyopathy.
In principle, this goal could be achieved by using two gen-
eral approaches, namely, by exogenous delivery of cardiomy-
ocytes or other cell types with a potential for cardiac dif-
ferentiation, or by stimulating endogenous cardiomyogenesis
through appropriate small molecules or nucleic acids, either
individually or in combination.
Early claims of transdifferentiation of murine bone
marrow- (BM-) derived hematopoietic stem cells (HSCs)
into cardiomyocytes after delivery to infarcted mouse hearts
[1] were questioned by subsequent studies [2, 3]. However,
these negative results did not prevent clinical studies of cell
therapy for ischemic heart disease from being initiated [4–
10]. A majority of the clinical trials utilized autologous BM-
derived mononuclear cells delivered either into the target
coronary artery or directly into the peri-infarct region [5–
10]. Additional cell types that have been tested clinically in
patients after MI include autologous skeletal myoblasts [11,
12], both autologous and allogeneic BM-derived mesenchy-
mal stem cells (MSCs) [13], purified BM-derived populations
such as CD133+ cells [4, 14], autologous BM-derived MSCs
pretreated ex vivo with molecules that stimulate cardiomyo-
genic specification [15], autologous adipose tissue-derived
cells [16], as well as stem and progenitor cells derived from
the heart itself [17, 18]. Almost ten years after the initiation
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of randomized, controlled clinical trials of BM cell therapy
for cardiac regeneration, it must be recognized that results
have been inconsistent, and that the overall improvement of
cardiac function in MI patients has been modest [19–21].The
optimal timing of cell transplantation, the delivery technique,
and the most effective cell type remain to be defined. It also
has been shown that reduced cell functionality in old patients
and in those with advanced cardiovascular disease or comor-
bidities limits the benefits of autologous cells [22]. Hence,
an unresolved paradox persists between robust effects of cell
therapy in animal models and modest benefits in patients.
In principle, cardiac-derived stem and progenitor cell popu-
lations may offer major advantages over extracardiac cell
sources, as cardiac progenitorsmight bemore prone to differ-
entiate along the cardiomyocytic and vascular lineages and
to survive in the myocardial environment [23, 24]. Most
recently, two phase-1 clinical trials of autologous cardiac stem
cell therapy in patients after acute MI have shown that these
approaches are both safe and promising [17, 18].
2. Ex Vivo Tissue Explant Cultures,
‘‘Spheres,’’ and Stemness
The first report that cardiac progenitor cells can be clon-
ally expanded from murine and human myocardial biopsy
specimens and form “spheres” in vitro came from Messina
et al. [25]. Surgical atrial appendage specimens placed in the
primary ex vivo tissue culture spontaneously shed a heteroge-
nous cell population, the cellular outgrowth. Remarkably, we
have observed that cardiac explants keep shedding cells for
more than one year in the ex vivo culture [26], providing
direct evidence for the existence of cells within the tissue
explant that are able to proliferate in long term even in the
absence of blood supply. When cultured in cardiosphere-
(CS-) forming medium (a base medium supplemented with
basic fibroblast growth factor, epidermal growth factor,
cardiotrophin-1, thrombin, and B27 as a serum substitute)
and the nonadhesive substrate poly-D-lysine, the cellular
outgrowth gives rise to CSs (Figure 1(a)). Spheres are self-
assembling, multicellular, and floating cell clusters. Sphere-
forming cellsmay lose, in part, anchorage-dependent growth.
First described in neural stem cells [27], spheres have been
considered—or named, at least—as a characteristic feature
of stemness. However, it is now well recognized that sphere
formation is not sufficient to establish stemness [28, 29]. In
fact, spheres can be either clonal or nonclonal. Decreasing cell
density in culture dishes typically increases the proportion of
clonal spheres, which result from clonal cell proliferation. By
contrast, nonclonal spheres result fromboth proliferation and
cell aggregation.
3. CSs in Rodents
The early cellular outgrowth from murine cardiac explants
forms a layer of fibroblast-like cells on which numer-
ous small round “phase-bright” cells appear with a delay
of 1 to 2 weeks [26, 30]. The cellular outgrowth from
neonatal mouse cardiac explants is heterogeneous and con-
tains both hematopoietic (CD45+) and nonhematopoietic
(CD45−) cells. The latter include differentiation lineage-
negative (Lin−), c-kit+ (CD117) progenitor cells, endothelial
cells and endothelial progenitor cells (CD31+ and/or CD34+),
as well as mesenchymal/stromal progenitor cells (CD90+ and
CD105+) [26, 30–34]. Davis et al. [33] recently proposed that
the CD45+ subset within cellular outgrowths may result from
a retained hematologic component, which was minimized by
perfusing the heart with heparinized saline before placing
the tissue explants in the culture dishes. Approximately 10%
of cells shed by mouse cardiac explants during the first few
days express c-kit, stem cell antigen-1 (Sca-1), the stem and
progenitor cell-related antigen CD34, and the endothelial
marker CD31. We have shown that CSs are composed
of clonally derived cells that consist of proliferating cells
primarily in their core, including a subset of c-kit+ cells,
along with an outer sheet of early committed progenitors
and differentiating cells that express cardiac, endothelial,
and stromal markers. CSs from transgenic mice expressing
a nuclear lacZ reporter gene driven by the cardiac-specific
cTnI promoter exhibited lacZ expression mainly in the outer
sheet [35]. By video microscopy, we have demonstrated
spontaneous beating of CSs from neonatal, but not adult,
mouse cardiac explants in the absence of coculture with
mature cardiomyocytes [26]. Recently, Andersen et al. [34]
challenged the view that CS-derived cells (CDCs) are a
source of stem cells with cardiomyogenic potential. These
authors showed that CSs from neonatal mice may contain
small myocardial fragments that detached from the tissue
explant, especially when this is not removed from the cell
culture, as neonatal mouse explants become less cohesive
after prolonged periods of time in culture. To address this
question, we used Z/EG transgenic mice in which cardiac-
specific expression of Cre-recombinase results in the excision
of a lacZ gene and activation of expression of the second
reporter gene (EGFP) in the heart [36]. Following Cre-
recombinase gene transfer into the heart before the initiation
of the ex vivo tissue culture, EGFP expression was observed
in Z/EG cardiac explants but not in their cellular outgrowths,
indicating that the latter lacked mature cardiomyocytes
resulting from small tissue fragments detaching from the
explant [26]. When cardiac explants were cultured in com-
plete MesenCult MSC medium, a commercially available
medium developed forMSC cultures, as opposed to standard
media utilized in the original protocol [25], a relatively
homogeneous population of plastic-adherent cells expressing
hematopoietic and monocyte/macrophage markers (CD45+
andCD14+) and exhibitingMSC-like differentiation potential
was obtained. At high densities, these cells formed CSs that
lost adhesion to plastic and detached from culture dishes [26],
even when cultured directly on plastic. These observations
suggest that different experimental conditions may result in
the preferential expansion of different cell populations from
a heterogeneous early cellular outgrowth. Recently, Ye et al.
[37] addressed the question whether the CD45+ cells are
an essential component in CS formation. They harvested
CSs from 1-week post-MI mouse hearts or from healthy
hearts. CD45+ cells were depleted from populations of CS-
forming cells by immunomagnetic beads. The depletion of
CD45+ cells from these populations actually increased the
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Figure 1: (a) Photomicrographs of a human atrial appendage specimen in the primary culture giving rise to a cellular outgrowth (left panel);
CSs (middle panel); CDCs (right panel). (b) High magnification view of a human CS. (c) Flow-cytometric analysis of cell-surface marker
expression by CS-forming cells (top to bottom: plots for CD45 versus CD166, CD45 versus NG2, and CD45 versus CD105 expression).
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Figure 2: Electron-microscopical analysis of human CS ultrastructure. (a) Secretory granules (red arrows); primary lysosomes (yellow
arrows). (b) Intercellular contacts (blue arrows). (c) Intracellular, unorganized thick filaments (green arrows); dense bodies (asterisks). (d)
Mitosis (N, nucleus; G, Golgi apparatus; rER, rough endoplasmic reticulum).
formation of CSs compared with nondepleted populations.
PurifiedCD45+ cells fromCS-forming cells did not formCSs,
indicating that BM-derivedCD45+ cells are neither necessary
nor sufficient for CS formation.
4. Human CSs Contain Both
Primitive Cells and Cells Differentiating
into Cardiomyocytes
We have generated human CSs from cells spontaneously
shed from cultured surgical atrial appendage specimens
from patients undergoing heart surgery for coronary artery
disease or heart valve disease. However, CSs can also be
obtained from human percutaneous endomyocardial biopsy
specimens [38]. CSs placed in a new culture dish disassemble
and give rise to a monolayer of CDCs that are clonogenic,
can be expanded on fibronectin, and can give rise to a
second generation of spheres. CS-forming cells express MSC
markers [39] such as CD105 (endoglin, a part of the TGF-
𝛽1 receptor complex), CD13 (aminopeptidase N), and CD73
(lymphocyte-vascular adhesion-protein 2), as well as CD166
(activated leukocyte cell adhesion molecule; ALCAM; Figure
1(c)). Subsets of these cells also express NG2 chondroitin
sulfate proteoglycan and CD140b (platelet-derived growth
factor receptor B), which have been associated with per-
icytes/perivascular cells and MSCs in many tissues [40].
However, the cellular outgrowth does not express CD45 and
CD34.
By electron microscopy, we have provided ultrastructural
evidence of the presence of secretory granules, intercellular
contacts, mitotic cells, and unorganized thick filaments con-
sistent with cardiac progenitors/precursors within human
CSs (Figure 2). In line with previous studies [15, 38], we
have shown that human CSs express both early (Nkx2.5 and
GATA4) and late (cTnI, 𝛼-sarcomeric actinin) cardiac genes
(Figure 3).We also have shown that cardiac troponin I and 𝛼-
sarcomeric actinin in association with sarcomeric structures,
aswell as connexin 43, are detectable immunocytochemically,
most abundantly in the outer layer ofCSs. By contrast, cellular
outgrowths from cultured cardiac tissue explants, fromwhich
CSs are derived, do not express these sarcomeric proteinsg.
It has been shown that human cardiac cellular outgrowths
cocultured with neonatal rat ventricular myocytes exhibit
spontaneous, synchronous beating activity [35]. Moreover,
differentiation of human adult CDCs could be stimulated by
exposure to extremely low-frequency electromagnetic fields
[41]. The CS method has also been used to enrich c-kit+ [42]
and Sca-1+ cardiac cells [43].
5. Human Cardiospheres Recapitulate Stem
Cell Niche Properties In Vitro
Anversa et al. [44] first postulated that CSs may recapitulate
ex vivo several features of cardiac stem cell niches, as
described in vivo. This notion is supported by data by Li et
al. [45]. Expression of connexin 43, a gap junction protein
playing a key role for the electric coupling of differentiating
cardiac progenitors with the surrounding cells, suggests that
the differentiated cells may serve as supporting cells for
the more primitive cells. Cells self-assembled into niche-like
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Figure 3: (a) Immunostaining of a human CS showing cells expressing cardiac 𝛼-sarcomeric actinin (red) in the outer sheet; nuclear staining
with DAPI (blue). (b) PCR expression analysis of early and late cardiac genes by CS-forming cells (CfCs), CSs, and human cardiac biopsy
tissue. CfCs express lower levels of early genes (Nkx2.5 and GATA4 transcription factors) compared to CSs, but no 𝛼-sarcomeric actinin (SA)
nor cardiac troponin I (cTnI). CSs express high levels of both early and late cardiac genes.
CS structures exhibit greater proportions of c-kit+ cells and
upregulation of embryonic genes such as SOX2 and Nanog
compared to cells cultured under traditional monolayer
conditions or cells dissociated from CSs. Quantitative RT-
PCR and immunostaining data show increased expression
of stem cell-related factors and adhesion/extracellular-matrix
(ECM) molecules in CSs, including insulin-like growth
factor 1 (IGF-1), histone deacetylase 2 (HDAC2), telom-
erase (Tert), integrin-𝛼2, laminin-𝛽1, and matrix metallo-
proteinases (MMPs) compared to the above populations
not assembled in CSs. Dissociation of CSs into single cells
decreases the expression of ECM and adhesion molecules,
reduces the resistance of cells to oxidative stress, and abro-
gates the advantages of CSs in terms of in vivo engraftment
and functional improvement after MI. Thus, CSs mimic
several features of cardiac stem cell niches, including the pres-
ence of both primitive and differentiating cells and expression
of ECM and adhesion molecules, which are associated with
enhanced in vivo cell survival and cardioprotection after MI.
6. Human CS and CDC Therapy in
Animal Models
CDCs reduced scarring after MI, increased viable myocard-
ium, and boosted cardiac function in preclinical animalmod-
els [25, 38, 45–49]. In the initial study by Messina et al. [25],
human CSs were injected into the viable myocardium bor-
dering a freshly infarcted area in SCID mice. Eighteen days
after the intervention, infarct size did not significantly differ
between the CS-treated group and the PBS-injected group.
However, percent fractional shortening was higher in the
former group (36.85% ± 16.43% versus 17.87% ± 5.95%; 𝑃 <
0.05). Vigorous engraftment with bands of regeneratingmyo-
cardiumandnewly formedblood vesselswere observed in the
CS-treated group.
Smith et al. [38] reported that percutaneous endomyocar-
dial biopsy specimens grown in primary culture developed
CSs (in 69 of 70 patients), from which CDCs were obtained.
HumanCDCswere injected into the border zone of acuteMIs
in immunodeficientmice. CSs andCDCs expressed antigenic
characteristics of stem cells at each stage of processing, as
well as proteins essential for cardiac contractile and electrical
function.HumanCDCs coculturedwith neonatal rat ventric-
ular myocytes exhibited biophysical signatures characteristic
of myocytes, including calcium transients synchronous with
those of neighboring myocytes. Human CDCs injected into
the border zone of MIs engrafted and migrated into the
infarct zone. After 20 days, both the percentage of viable
myocardium within the MI zone and left ventricular ejection
fraction were greater in the CDC-treated group compared
with the fibroblast-treated control group.
Chimenti et al. [46] showed that human adult CSs and
CDCs release many growth factors in culture media, which
mediate both proangiogenic effects on human umbilical
vein endothelial cells and antiapoptotic effects on neonatal
rat ventricular myocytes in vitro. When transplanted into
the peri-infarct zone in a SCID mouse MI model, human
CDCs secreted vascular endothelial growth factor 1 (VEGF1),
hepatocyte growth factor (HGF), and IGF1. These effects
were associated with the upregulation of the prosurvival
factor Akt, reduced the activation of caspase 3 and apoptosis,
increased capillary density, and improved cardiac function.
The relative contribution of the paracrine effects of the trans-
planted human CDCs versus their direct differentiation into
cardiovascular cells was assessed by immunohistochemistry
using two different antibodies raised against human-specific
epitopes. The number of human-specific cells relative to
overall increases in capillary density and myocardial viability
indicated that direct differentiation of the transplanted cells
accounted for 20% to 50% of the observed effects.These find-
ings demonstrate that transplanted human CDCs act mainly
by stimulating endogenous cardiac regeneration through
paracrine mechanisms, while direct cardiac differentiation of
CDCs in situ is also playing contributory roles.
Recently, Li et al. [47] conducted a direct comparison
between different stem cell types in vitro for various assays
of cell potency and in vivo for functional myocardial repair
in the same mouse MI model. In vitro, human CDCs showed
the greatest myogenic differentiation potency, the highest
angiogenic potential, and relatively high production of sev-
eral angiogenic and antiapoptotic factors compared with
humanBM-derivedMSCs, adipose tissue-derivedMSCs, and
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BM-derived mononuclear cells. In vivo, injection of CDCs
into infarctedmouse hearts resulted in superior improvement
of cardiac function, the highest cell engraftment and myo-
genic differentiation rates, the lowest number of apoptotic
cells, and the least-abnormal heart morphology 3 weeks after
treatment. The c-kit+ subpopulation purified from CDCs
produced lower levels of paracrine factors and mediated
lower functional benefits compared with unsorted CDCs.
It should be noted, however, that these c-kit+ cells were
purified from CDCs and not directly from cardiac tissue
specimens, which represents a methodological difference to
the recent SCIPIO trial [17]. To validate the comparison of
cells from various human donors, results were verified in cells
of different types derived from individual rats. These data
demonstrate that CDCs have greater regeneration potential
compared to other cell types currently used for cardiac repair.
7. Autologous versus Allogeneic CDC Therapy
in Animal Models
Malliaras et al. [49] compared between syngeneic, allo-
geneic, and xenogeneic CDCs for cardiac regeneration. In
vitro, CDCs expressed major histocompatibility complex
(MHC) class I but not class II antigens or B7 costimulatory
molecules. In mixed-lymphocyte reactions, allogeneic CDCs
elicited negligible lymphocyte proliferation and inflamma-
tory cytokine secretion. In vivo, syngeneic and allogeneic
CDCs survived at similar levels in rat hearts 1 week after cell
delivery, but few syngeneic (and even fewer allogeneic) CDCs
persisted at 3 weeks. Allogeneic CDCs induced a transient,
mild, and local immune reaction in the heart, without
histologically evident rejection or systemic immunogenicity.
Improvements in cardiac structure and function were com-
parable with syngeneic and allogeneic CDCs up to 6 months
after cell delivery. Allogeneic CDCs stimulated endogenous
regenerative mechanisms (cell cycling, recruitment of c-kit+
cells, and angiogenesis) and increased myocardial VEGF1,
IGF1, andHGF equally with syngeneic CDCs.Thepersistence
of benefit despite a transient survival of the transplanted
cells suggested an indirect mechanism of action involving
paracrine effects.These results indicated that allogeneic CDC
therapy without immunosuppression was safe and improved
heart function in a rat model of myocardial infarction.
As such, allogeneic CDCs might obviate the limitations
associated with patient-specific tissue harvesting and cell
processing, suggesting that allogeneic humanCDCsmay rep-
resent a potential off-the-shelf product for cell heart therapy.
8. Clinical Testing of CDC Therapy in
Patients after MI
The results of the prospective, randomised cardiosphere-
derived aUtologous stem cells to reverse ventricular dySfunc-
tion (CADUCEUS) trial (registered with ClinicalTrials.gov,
NCT00893360) were published recently [18]. Patients 2–
4 weeks after MI (with depressed left ventricular ejection
fraction of 25–45%) were enrolled at two medical centers in
the USA and randomly allocated in a 2 : 1 ratio to receive
CDCs (𝑛 = 17) or standard care (𝑛 = 8). For patients assigned
to receive CDCs, autologous cells were grown from endomy-
ocardial biopsy specimens. Prescribed cell doses were
achieved within 36 ± 6 days (mean ± SD) and infused into
the infarct-related artery 1.5–3 months after MI.The primary
endpoint was proportion of patients at 6 months who died
due to ventricular tachycardia, ventricular fibrillation, or
sudden unexpected death or had MI after cell infusion, new
cardiac tumor formation on MRI, or a major adverse cardiac
event (composite of death and hospital admission for heart
failure or nonfatal recurrent MI). Preliminary efficacy data
were collected using cardiac magnetic resonance imaging
(MRI) at 6 months. No complications were reported within
24 h of CDC infusion. By 6 months, no patients had died
or developed cardiac tumors, or major adverse cardiac event
in either group. Four patients (24%) in the CDC group had
serious adverse events compared with one control (13%; 𝑃 =
1.00). Compared with controls at 6 months, MRI analysis of
patients treated with CDCs showed reductions in scar mass
(𝑃 = 0.001) and increases in viable heart mass (𝑃 = 0.01)
and regional contractility (𝑃 = 0.02) as well as regional sys-
tolic wall thickening (𝑃 = 0.015). However, changes in end-
diastolic volume, end-systolic volume, and left ventricular
ejection fraction did not differ between groups by 6 months.
These results indicate that intracoronary infusion of autolo-
gous CDCs after MI is safe. The observed increase in viable
myocardium suggests that therapeutic regenerationmay have
occurred.
9. Cell Therapy versus Secreted Factors
The demonstration of beneficial effects of cell therapy despite
short-lived survival of the delivered cells [49], together with
the observed trophic effects on culture media conditioned by
progenitor cells [46], suggests that secreted factors may be
the active component of cell therapy for cardiac regeneration.
Cells communicate with each other via released molecules
such as short peptides, proteins, nucleotides, and lipids that
bind to surface receptors on neighboring cells. In addition,
eukaryotic cells communicate with each other through the
release of microparticles and exosomes in their extracellular
environment. Exosomes are membrane vesicles (40–100 nm
in diameter) formed by endocytosis. They are smaller than
microparticles (100–1000 nm in diameter), which are released
by budding of the plasma membrane (ectocytosis) [50].
Exosomes display a broad spectrum of bioactive substances
on their surfaces and carry a concentrated set of proteins,
lipids, and even nucleic acids that are taken up by other cells
and regulate their function [51–53]. Sahoo et al. [54] reported
angiogenic effects of exosomes derived from human CD34+
BM stem cells in isolated endothelial cells andmurinemodels
of vessel growth. In some of the in vitro and in vivo assays,
the exosomes from CD34+ cells appeared more potent than
the cells themselves. Vrijsen et al. [55] reported that exosomes
mediated the angiogenic activity of media conditioned by
human fetal cardiac progenitor cells in vitro. Timmers et al.
[56] showed that injection of media conditioned by ESC-
derived MSCs reduced infarct size and improved cardiac
function in a pig model of ischemia/reperfusion injury,
Stem Cells International 7
and that exosomes within the conditioned medium con-
tained the active component. Lai et al. [57] found that
exosomes secreted by MSCs similarly reduced myocardial
ischemia/reperfusion (I/R) injury in mice. Barile et al. [58]
recently showed that exosomes isolated from mouse cardiac
progenitor cells protected H9C2 from oxidative stress by
inhibiting caspase 3/7 activation in vitro, while also reducing
cardiomyocyte apoptosis in a mouse model of myocardial
I/R in vivo. We have provided ultrastructural evidence of
exosome secretion by adult human CSs [59]. Further studies
are needed to assess whether exosomes isolated from CSs
are as cardioprotective as the respective cells of origin.
Of note, exosomes may offer major advantages over cell
transplantation for therapeutic applications. First, it might
be possible to use exosomes secreted by cells from young,
healthy individuals for allogeneic applications, even though
this hypothesis remains to be verified. This possibility would
pave the way to “off-the shelf ” exosome-based therapeutic
products. Second, exosomes can be storedwithout potentially
toxic cryopreservatives at −20∘C for 6 months with no loss
in their biochemical activities [60]. Third, exosomes protect
their contents from degradation in vivo [61, 62], thereby
potentially preventing some of the problems associated with
small soluble molecules such as cytokines, growth factors,
transcription factors, and RNAs, which are rapidly degraded.
Increasing evidence suggests that exosomes may act as
a vector of genetic information. Indeed, mRNAs carried
by exosomes can be translated into proteins in the target
cell. Accordingly, ESC-derived microvesicles were shown to
reprogram hematopoietic progenitors by mRNA transfer and
protein delivery [63]. MicroRNA families can be selectively
secreted into the extracellular environment through exo-
somes [64].
10. Cell versus Gene Therapy
Gene therapy may provide an alternative to cell transplan-
tation for cardiac protection and repair. Clearly, the two
approaches can be used in combination by transplanting
genetically engineered cells. Gene therapy has a potential
for circumventing some hurdles associated with cell therapy,
such as the need for in vitro cell expansion; however, it also
has peculiar limitations, such as the need for using either
viral or nonviral gene transfer vectors. Fujii et al. [65] recently
showed that ultrasound-targeted gene delivery of vascular
endothelial growth factor (VEGF) or stem cell factor (SCF)
induced angiogenesis and improved ventricular function
after MI in mice. Yaniz-Galende et al. [66] reported cardiac
repair by soluble SCF gene transfer afterMI via in situ recruit-
ment and expansion of c-kit+ cells. This observation is in line
with increased capillary density and reduced apoptosis in the
peri-infarct area in a mouse model of tetracycline-inducible,
cardiac-specific overexpression of membrane-associated SCF
[67].
Exosomes carry microRNA molecules [58, 64], as men-
tioned above, which may play key regulatory roles in many
processes such as cardiomyocyte proliferation [68], differen-
tiation [69], hypertrophy [70], as well as aging and function
[71]. Eulalio et al. [68] recently showed that exogenous
administration of two microRNAs (hsa-miR-590 and hsa-
miR-199a), which were identified by high-throughput func-
tional screening for human microRNAs that promoted
neonatal cardiomyocyte proliferation using a whole-genome
microRNA library, markedly stimulated cardiomyocyte pro-
liferation in both neonatal and adult rodents. After MI in
mice, these microRNAs stimulated marked cardiac regen-
eration and almost complete recovery of cardiac functional
parameters. Adenoassociated virus- (AAV-) based vectors
were used to deliver microRNAs in vivo. Further studies
are needed to evaluate whether these microRNAs likewise
induce proliferation in human cardiomyocytes. Boon et al.
[71] recently reported that miR-34a was induced in the aging
heart and that in vivo silencing or genetic deletion of miR-
34a reduced age-associated cardiomyocyte cell death. More-
over, miR-34a inhibition reduced cell death and fibrosis,
while improving myocardial function after acute MI in mice.
PNUTS, a novel direct miR-34a target, reduced telomere
shortening, DNA damage responses, and cardiomyocyte
apoptosis, thereby improving cardiac function after acuteMI.
11. Conclusions
CSs have attracted great interest as an in vitromodel of a stem
cell niche-like microenvironment rich in both primitive and
differentiating cells, and as a cell source for cell heart therapy.
The cellular outgrowths from cultured tissue explants may
enrich progenitor cells that migrate out of the explant. More-
over, both cell-cell and cell-matrix interactions within CSs
may promote the specification of cardiac-resident progen-
itors towards cardiovascular fates. CDCs have proven safe in
a phase-1 clinical trial in patients after MI, and initial results
have been promising. Meanwhile, exosomes and microRNAs
are emerging as alternate, cell-free strategies for cardiac pro-
tection and regeneration.
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